GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (OTCPK:BLCM) » Definitions » PS Ratio

Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) PS Ratio

: 1.56 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bellicum Pharmaceuticals's share price is $0.07475. Bellicum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.05. Hence, Bellicum Pharmaceuticals's PS Ratio for today is 1.56.

Good Sign:

Bellicum Pharmaceuticals Inc stock PS Ratio (=1.56) is close to 10-year low of 1.55

The historical rank and industry rank for Bellicum Pharmaceuticals's PS Ratio or its related term are showing as below:

BLCM' s PS Ratio Range Over the Past 10 Years
Min: 1.55   Med: 63.61   Max: 2340
Current: 1.56

During the past 11 years, Bellicum Pharmaceuticals's highest PS Ratio was 2340.00. The lowest was 1.55. And the median was 63.61.

BLCM's PS Ratio is ranked better than
87.65% of 996 companies
in the Biotechnology industry
Industry Median: 8.985 vs BLCM: 1.56

Bellicum Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2023 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.05.

Warning Sign:

Bellicum Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Bellicum Pharmaceuticals was -25.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -68.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -23.50% per year.

During the past 11 years, Bellicum Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 119.60% per year. The lowest was -79.90% per year. And the median was -21.85% per year.

Back to Basics: PS Ratio


Bellicum Pharmaceuticals PS Ratio Historical Data

The historical data trend for Bellicum Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.04 8.46 40.57 2.76 14.69

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.75 14.69 6.88 7.71 6.88

Competitive Comparison

For the Biotechnology subindustry, Bellicum Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's PS Ratio falls into.



Bellicum Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Bellicum Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.07475/0.048
=1.56

Bellicum Pharmaceuticals's Share Price of today is $0.07475.
Bellicum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Bellicum Pharmaceuticals  (OTCPK:BLCM) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Bellicum Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.
Executives
Charity Scripture officer: Chief Development Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Stephen Davis director ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Charles S. Grass officer: Principal Accounting Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Fair director, officer: President and CEO C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
David Eric Strauss officer: Director, Corporate Controller 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Shane Ward officer: Sr. VP and General Counsel C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Woodard Jr Joseph Paul officer: SVP Clinical & Medical Affairs C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Aaron E. Foster officer: Sr VP, Head of Research C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030
Rosemary Y. Williams officer: Principal Accounting Officer 2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030
Judith V Klimovsky director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Atabak Mokari officer: Sr. VP and CFO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Jon P Stonehouse director 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
David M. Spencer officer: Chief Scientific Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Alan A Musso officer: CFO and Treasurer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139